drugset / Trial / NCT02934503
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NaSingle-groupOpen-labelTreatment
Summary
This trial is to assess the efficacy of pembrolizumab added to concurrent chemotherapy with or without radiation therapy in patients with small cell lung cancer (SCLC).
Timeline
- Start
- 2017-01-23
- Primary completion
- 2019-10-01
- Completion
- 2019-10-01
Outcome
Outcome not reported
Stopped: “This study was terminated as the standard of care for small cell lung cancer changed in 2018 to include immunotherapy in the front line setting, making this study no longer clinically relevant.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |